Distalmotion Brand Guidelines: The EPFL Spin-Off Behind the Dexter Surgical Robot

A robot designed around the surgeon’s day.

Distalmotion was founded in 2012. The company says it began as a spin-off from the robotics laboratory of the Swiss Federal Institute of Technology in Lausanne (EPFL), and it describes itself as headquartered in Lausanne; its registered address is in neighbouring Epalinges, and the Swiss start-up news site startupticker.ch calls it “Biopôle-based,” after the life-sciences campus there. In its early years the name was often written as two words, Distal Motion, or as DistalMotion; the company now writes it as one word, Distalmotion.

Early money came from Swiss venture investors. In June 2019 startupticker.ch reported that BlueOcean Ventures, an investor in Distal Motion SA since 2013, had sold its entire stake.

The idea behind the product was set out in a startupticker.ch article by Stefan Kyora in November 2018. Most surgical robots, it said, traced their roots to remote surgery and had become complex systems that needed a lot of training. Distalmotion’s robot, Dexter, had been designed around the daily work of surgeons: it would take on long and complex tasks such as suturing and dissection, while the surgeon kept short and specialised tasks such as stapling. The surgeon would not leave the operating table to control it, but could stay sterile beside the patient and switch between robotic and ordinary laparoscopic work in less than 20 seconds.

The same article described the commercial plan at the time: the robot would be rented rather than sold, with recurring income from consumables, and the company had its own sales teams for Germany, Switzerland, Austria and France. Its first distribution agreement, announced that week, gave Elemental Healthcare, a subsidiary of the British firm Surgical Innovations Group, three years of exclusive distribution in the UK.

Dexter, from design award to De Novo.

Dexter was recognised for its design before it reached patients. In February 2020 startupticker.ch reported that Distalmotion had won an iF Design Award 2020 for the system, one of 54 Swiss winners that year. The description published with the news said the design brings surgeons back to the patient, lets them switch quickly between manual and robotic surgery, and lets them work seated or standing.

European clearance followed at the end of that year. A company announcement carried by startupticker.ch on 29 December 2020 reported that Dexter had received the European CE mark; the company says the marking covered urology, gynaecology and general surgery. The announcement described Dexter as manufactured in Switzerland and quoted Michael Friedrich as chief executive. The company says Dexter performed its first clinical cases in 2021.

In the United States, the FDA’s De Novo database lists request DEN230084 for the “Dexter L6 System,” received in December 2023 and granted on 25 October 2024. The decision created a new device classification, which the FDA describes as an electromechanical surgical system in which the surgeon and the user interface can be in the sterile field. Several 510(k) clearances for the Dexter L6 System followed in 2025 and 2026.

The first American sale came soon after. In March 2025 startupticker.ch carried the company’s announcement that the Memorial Hermann Health System in Houston, Texas, had bought a Dexter system. The company now lists its US indications as laparoscopic inguinal and ventral hernia repair, gallbladder removal, benign hysterectomy and sacrocolpopexy, for adults.

The category.

Surgical robotics companies sell machines that most people will never see in use, so their public image is built from a small set of scenes. The commonest is the operating theatre itself: robot arms draped and angled over a table, a console set a few steps away, and a surgical team in scrubs around them. When the BBC reported a new British surgical robot in 2018, one of its pictures showed a surgeon steering a robot from a console.

The second scene is the surgeon’s own view. Many systems give the surgeon a 3D screen or viewer and hand controls, and company photographs often show a surgeon leaning into that viewer or working the controls, sometimes beside a screen showing the magnified view inside the body. Close-ups of instruments follow: slim shafts, small jaws and wristed tips that bend and turn, shown at a scale no visitor to a hospital would normally see.

Clean product renders do much of the remaining work. Arms, carts and consoles are shown against plain white or soft grey grounds, with a restrained palette of whites, greys and a single brand colour, so that the machine reads as precise and calm. Museums have started to collect the results; in 2023 the Science Museum in London put a surgical robot arm on show in its Engineers gallery.

The industry meets at its own congresses. In North America, the annual meeting of SAGES, the Society of American Gastrointestinal and Endoscopic Surgeons, is a regular venue for new systems; in Europe there is the annual congress of the EAES, the European Association for Endoscopic Surgery; and in London the Hamlyn Symposium on Medical Robotics brings engineers and surgeons together. The companies in this guide range from established makers to closed ventures, and each guide sets out what can be checked about them.

An independent Swiss company with American backers.

Distalmotion remains privately held. In January 2026 startupticker.ch carried the company’s announcement of a strategic investment from Johnson & Johnson, through its corporate venture arm, Johnson & Johnson Innovation; the same announcement named Revival Healthcare Capital as the leader of an earlier Series G round. The company said the money would support Dexter’s expansion into American ambulatory surgery centres, the outpatient sites it has positioned the robot for, and that more than 3,000 patients had by then been treated with the system in Europe and the United States.

The company describes its own scale in people rather than sites: more than 150 team members, of more than 25 nationalities, speaking over 15 languages, with the head office in the Lausanne area. Its pitch is built on operating-room practicality: the company says Dexter is small and mobile enough to move between rooms, that its open architecture lets surgeons keep their preferred visualisation and advanced devices, and that its draped console keeps the surgeon inside the sterile field.

The product name has its own styling. On its website the company writes DEXTER in capitals with a registered-trademark sign, while press coverage and FDA records use the ordinary spelling, Dexter. The FDA lists the requester for the De Novo decision as Distalmotion SA of Epalinges, matching the address the company gives on its own website.

For a design guide, Distalmotion shows a university spin-off presenting one robot through a single idea, the surgeon who stays at the patient’s side, from its first press coverage to its US launch. Compare Asensus Surgical, another robot maker that built its system around laparoscopic habits, and Johnson & Johnson, now among its investors. For this guide we use alpine graphite, sterile teal and Biopôle mist with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Distalmotion’s identity on hand — save it to a board in the Made Good inspiration library.